Gilead Sciences (GILD) 113.05 $GILD
5 Health Care Stocks to Trade for Gains -- Must-See Charts
at The Street - 57 mins ago
Health care stocks have been persistent outperformers in 2015. Here are five to trade now.
GILD: 113.05 (+2.51), UTHR: 167.30 (+1.52), SHPG: 263.19 (+4.08), EW: 153.98 (+1.26), IDXX: 65.75 (-0.55)
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts
ESRX: 91.69 (+0.59), GILD: 113.05 (+2.51), ACHN: 8.51 (+0.23), MRK: 57.32 (+0.33), ABBV: 70.83 (+1.49)
Avoid Gilead Shares for Now
at The Street - Tue Jul 28, 7:00AM CDT
Competition and lower earnings cloud its future.
GILD: 113.05 (+2.51), MRK: 57.32 (+0.33), ABBV: 70.83 (+1.49)
Are These 2 Big Pharmas Really Buyout Candidates?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 28, 6:42AM CDT
Source: Pixabay The pharmaceutical industry is undergoing an unprecedented amount of consolidation right now due to an influx of cash from several new classes of drugs and the need to replace former blockbusters that have lost patent...
GILD: 113.05 (+2.51), PFE: 35.21 (+0.87), AZN: 32.85 (+0.14), BMY: 64.44 (+0.14)
3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 317.50 (+8.07), GILD: 113.05 (+2.51), CELG: 135.87 (+3.31)
Fed Meeting, Twitter Earnings, Consumer Data in Focus Tuesday
at The Street - Mon Jul 27, 7:15PM CDT
Merck, Pfizer, UPS and Twitter are among the many companies reporting earnings.
F: 14.89 (+0.34), PNRA: 184.00 (-0.01), GILD: 113.05 (+2.51), PFE: 35.21 (+0.87), MRK: 57.32 (+0.33), DD: 56.16 (-0.57), TWTR: 35.98 (+1.28), BWLD: 171.19 (+2.62), UPS: 100.23 (+5.11)
3 Stocks for Retirees to Buy
Brian Feroldi, Selena Maranjian, and Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 27, 6:03PM CDT
Photo by 401(k) 2012 / Flickr creative commons Investors who are in retirement should be looking for safe, reliable companies that offer good long-term growth prospects at a lower than average risk level. These types of investments tend to have...
SE: 30.16 (+0.95), GILD: 113.05 (+2.51), PG: 80.58 (+0.61)
Which Big-Cap Stocks Are Defying Market Pressure?
at Investor's Business Daily - Mon Jul 27, 5:46PM CDT
When an uptrend comes under pressure, some stocks show action worthy of a drumroll, while others inspire eye rolls. The recent trouble for the uptrend started after the July 20 close. The S&P 500 suffered four distribution days in a row through...
BIIB: 317.50 (+8.07), MNST: 149.73 (+0.97), VRX: 257.32 (+0.02), GILD: 113.05 (+2.51), CMG: 729.35 (-2.09)
Gilead Announces Executive Promotions
Business Wire - Mon Jul 27, 3:30PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of William Lee, PhD to Executive Vice President, Research, and Brett Pletcher to Executive Vice President and General Counsel. Dr. Lee and Mr. Pletcher will both join Gilead's senior leadership committee.
GILD: 113.05 (+2.51)
Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
at The Street - Mon Jul 27, 3:30PM CDT
People are "max negative" on Twitter ahead of its earnings report Tuesday, which Jim Cramer doesn't see as unjustified -- at least, in the short term.
AGN: 337.55 (+10.57), BIIB: 317.50 (+8.07), GILD: 113.04 (+2.50), TEVA: 71.13 (-0.87), TWTR: 35.98 (+1.28)
Is Gilead Sciences About to Make an Acquisition?
ESTMZ - Mon Jul 27, 2:24PM CDT
Gilead Sciences (GILD) reports its FQ2 ’15 results after the closing bell tomorrow. Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ. Estimize are forecasting an EPS figure of $2.77 and a revenue target of $7.540B. Wall...
SPY: 209.09 (+2.30), GILD: 113.04 (+2.50), ALXN: 203.03 (+4.93), ABBV: 70.83 (+1.49), NDAQ: 50.65 (-0.52)
4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 12:51PM CDT
Let's turn the spotlight this World Hepatitis Day on some hepatitis-focused companies poised to grow.
ESRX: 91.69 (+0.59), GILD: 113.04 (+2.50), ACHN: 8.51 (+0.23), MRK: 57.32 (+0.33), ABBV: 70.83 (+1.49), BMY: 64.44 (+0.14), NVS: 102.64 (+1.10)
Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings
at The Street - Mon Jul 27, 11:42AM CDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
GILD: 113.04 (+2.50), ABBV: 70.83 (+1.49)
Cramer -- Intel's a Few Bucks Away From a Buy, but PayPal Is One Right Now
at The Street - Mon Jul 27, 11:32AM CDT
Tech stocks were on the minds of viewers Monday morning when they posed their questions to TheStreet's Jim Cramer, including Intel, T-Mobile and PayPal.
BIIB: 317.50 (+8.07), GILD: 113.04 (+2.50), ALTR: 49.14 (+0.22), XON: 61.14 (+6.57), PYPL: 37.49 (+1.10), TMUS: 37.00 (+0.50), TWTR: 35.98 (+1.28), INTC: 28.91 (+0.56)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
PR Newswire Europe - Mon Jul 27, 11:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news [http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news]) has announced the addition of the "Key Pharma News Issue" [http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news] newsletter to their offering.
GILD: 113.04 (+2.50)
Gilead Sciences (GILD) Crosses Pivot Point Support at $111.28
Comtex SmarTrend(R) - Mon Jul 27, 10:46AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $114.21 and have already reached the first level of support at $111.28. Analysts will be watching for a cross of the next downside pivot targets of $109.72 and $105.23.
GILD: 113.04 (+2.50)
5 Stocks to Watch for this Week 7/27
ESTMZ - Mon Jul 27, 9:30AM CDT
Reports Tuesday, July 28 Report Wednesday, July 29 Report Thursday, July 30 Gilead Sciences (GILD) Gilead Sciences (GILD) reports its FQ2 ’15 results on Tuesday after the market close. Both Estimize and Wall Street are predicting...
F: 14.89 (+0.34), SPY: 209.09 (+2.30), LNKD: 226.52 (+5.86), GILD: 113.04 (+2.50), FB: 95.02 (+0.85), TWTR: 35.98 (+1.28), NDAQ: 50.65 (-0.52)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 317.50 (+8.07), AMZN: 525.34 (-6.07), MON: 101.01 (-0.45), COP: 52.84 (+2.19), AMGN: 172.94 (+7.40), XOM: 82.52 (+3.26), SLB: 82.89 (+1.13), CELG: 135.87 (+3.31), RIG: 14.16 (+1.05), GILD: 113.04 (+2.50), DD: 56.16 (-0.57), PX: 114.87 (+3.05), CVX: 92.45 (+3.31), DOW: 46.70 (+1.07), REGN: 557.59 (+17.56)
Ventricular Fibrillation - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkvvmk/ventricular) has announced the addition of the "Ventricular Fibrillation Global Clinical Trials Review, H1, 2015" report to their offering. "Ventricular Fibrillation Global Clinical Trials Review, H1, 2015" provides data on the Ventricular Fibrillation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ventricular Fibrillation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ventricular Fibrillation. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listing Top Companies/Institutions Participating in Ventricular Fibrillation Therapeutics Clinical Trials - Baxter International Inc. - Sanofi - Sandoz International GmbH - Ikaria Inc. - Gilead Sciences, Inc. - Gilead Sciences - National Heart, Lung, and Blood Institute - Assistance Publique - Hopitaux de Paris - Beaumont Health System - Department of Health, UK - Japan Heart Foundation - Japan Medical Association - Karolinska Institute - Klinikum der Ludwig-Maximilians-Universitat Munchen - Mayo Clinic - Rajaei Hospital For more information visit http://www.researchandmarkets.com/research/nk...entricular
GILD: 113.04 (+2.50), BAX: 38.08 (+0.38)
FCX, CLF, BIIB, COF: Jim Cramer's Views
at The Street - Mon Jul 27, 12:00AM CDT
Jim Cramer shares his views on a really bad day and when a leader stumbles. Freeport McMoRan, Google, Biogen and Capital One are among the many stocks discussed here.
BIIB: 317.50 (+8.07), COF: 78.35 (-0.26), GILD: 113.04 (+2.50), FCX: 12.49 (+1.12), RCPT: 227.76 (+0.67), CLF: 2.95 (+0.55), REGN: 557.59 (+17.56), CELG: 135.87 (+3.31)
5 Health Care Stocks to Trade for Gains -- Must-See Charts
at The Street - 57 mins ago
Health care stocks have been persistent outperformers in 2015. Here are five to trade now.
GILD: 113.05 (+2.51), UTHR: 167.30 (+1.52), SHPG: 263.19 (+4.08), EW: 153.98 (+1.26), IDXX: 65.75 (-0.55)
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts
ESRX: 91.69 (+0.59), GILD: 113.05 (+2.51), ACHN: 8.51 (+0.23), MRK: 57.32 (+0.33), ABBV: 70.83 (+1.49)
Avoid Gilead Shares for Now
at The Street - Tue Jul 28, 7:00AM CDT
Competition and lower earnings cloud its future.
GILD: 113.05 (+2.51), MRK: 57.32 (+0.33), ABBV: 70.83 (+1.49)
Are These 2 Big Pharmas Really Buyout Candidates?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 28, 6:42AM CDT
Source: Pixabay The pharmaceutical industry is undergoing an unprecedented amount of consolidation right now due to an influx of cash from several new classes of drugs and the need to replace former blockbusters that have lost patent...
GILD: 113.05 (+2.51), PFE: 35.21 (+0.87), AZN: 32.85 (+0.14), BMY: 64.44 (+0.14)
3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 317.50 (+8.07), GILD: 113.05 (+2.51), CELG: 135.87 (+3.31)
Fed Meeting, Twitter Earnings, Consumer Data in Focus Tuesday
at The Street - Mon Jul 27, 7:15PM CDT
Merck, Pfizer, UPS and Twitter are among the many companies reporting earnings.
F: 14.89 (+0.34), PNRA: 184.00 (-0.01), GILD: 113.05 (+2.51), PFE: 35.21 (+0.87), MRK: 57.32 (+0.33), DD: 56.16 (-0.57), TWTR: 35.98 (+1.28), BWLD: 171.19 (+2.62), UPS: 100.23 (+5.11)
3 Stocks for Retirees to Buy
Brian Feroldi, Selena Maranjian, and Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 27, 6:03PM CDT
Photo by 401(k) 2012 / Flickr creative commons Investors who are in retirement should be looking for safe, reliable companies that offer good long-term growth prospects at a lower than average risk level. These types of investments tend to have...
SE: 30.16 (+0.95), GILD: 113.05 (+2.51), PG: 80.58 (+0.61)
Which Big-Cap Stocks Are Defying Market Pressure?
at Investor's Business Daily - Mon Jul 27, 5:46PM CDT
When an uptrend comes under pressure, some stocks show action worthy of a drumroll, while others inspire eye rolls. The recent trouble for the uptrend started after the July 20 close. The S&P 500 suffered four distribution days in a row through...
BIIB: 317.50 (+8.07), MNST: 149.73 (+0.97), VRX: 257.32 (+0.02), GILD: 113.05 (+2.51), CMG: 729.35 (-2.09)
Gilead Announces Executive Promotions
Business Wire - Mon Jul 27, 3:30PM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of William Lee, PhD to Executive Vice President, Research, and Brett Pletcher to Executive Vice President and General Counsel. Dr. Lee and Mr. Pletcher will both join Gilead's senior leadership committee.
GILD: 113.05 (+2.51)
Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
at The Street - Mon Jul 27, 3:30PM CDT
People are "max negative" on Twitter ahead of its earnings report Tuesday, which Jim Cramer doesn't see as unjustified -- at least, in the short term.
AGN: 337.55 (+10.57), BIIB: 317.50 (+8.07), GILD: 113.04 (+2.50), TEVA: 71.13 (-0.87), TWTR: 35.98 (+1.28)
Is Gilead Sciences About to Make an Acquisition?
ESTMZ - Mon Jul 27, 2:24PM CDT
Gilead Sciences (GILD) reports its FQ2 ’15 results after the closing bell tomorrow. Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ. Estimize are forecasting an EPS figure of $2.77 and a revenue target of $7.540B. Wall...
SPY: 209.09 (+2.30), GILD: 113.04 (+2.50), ALXN: 203.03 (+4.93), ABBV: 70.83 (+1.49), NDAQ: 50.65 (-0.52)
4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 12:51PM CDT
Let's turn the spotlight this World Hepatitis Day on some hepatitis-focused companies poised to grow.
ESRX: 91.69 (+0.59), GILD: 113.04 (+2.50), ACHN: 8.51 (+0.23), MRK: 57.32 (+0.33), ABBV: 70.83 (+1.49), BMY: 64.44 (+0.14), NVS: 102.64 (+1.10)
Gilead Can Soothe Biotech Investor Fears with Great 2Q Earnings
at The Street - Mon Jul 27, 11:42AM CDT
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
GILD: 113.04 (+2.50), ABBV: 70.83 (+1.49)
Cramer -- Intel's a Few Bucks Away From a Buy, but PayPal Is One Right Now
at The Street - Mon Jul 27, 11:32AM CDT
Tech stocks were on the minds of viewers Monday morning when they posed their questions to TheStreet's Jim Cramer, including Intel, T-Mobile and PayPal.
BIIB: 317.50 (+8.07), GILD: 113.04 (+2.50), ALTR: 49.14 (+0.22), XON: 61.14 (+6.57), PYPL: 37.49 (+1.10), TMUS: 37.00 (+0.50), TWTR: 35.98 (+1.28), INTC: 28.91 (+0.56)
Key Pharma News Issue - Gilead will make further oncology deals in 2015
PR Newswire Europe - Mon Jul 27, 11:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news [http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news]) has announced the addition of the "Key Pharma News Issue" [http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news] newsletter to their offering.
GILD: 113.04 (+2.50)
Gilead Sciences (GILD) Crosses Pivot Point Support at $111.28
Comtex SmarTrend(R) - Mon Jul 27, 10:46AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $114.21 and have already reached the first level of support at $111.28. Analysts will be watching for a cross of the next downside pivot targets of $109.72 and $105.23.
GILD: 113.04 (+2.50)
5 Stocks to Watch for this Week 7/27
ESTMZ - Mon Jul 27, 9:30AM CDT
Reports Tuesday, July 28 Report Wednesday, July 29 Report Thursday, July 30 Gilead Sciences (GILD) Gilead Sciences (GILD) reports its FQ2 ’15 results on Tuesday after the market close. Both Estimize and Wall Street are predicting...
F: 14.89 (+0.34), SPY: 209.09 (+2.30), LNKD: 226.52 (+5.86), GILD: 113.04 (+2.50), FB: 95.02 (+0.85), TWTR: 35.98 (+1.28), NDAQ: 50.65 (-0.52)
Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 317.50 (+8.07), AMZN: 525.34 (-6.07), MON: 101.01 (-0.45), COP: 52.84 (+2.19), AMGN: 172.94 (+7.40), XOM: 82.52 (+3.26), SLB: 82.89 (+1.13), CELG: 135.87 (+3.31), RIG: 14.16 (+1.05), GILD: 113.04 (+2.50), DD: 56.16 (-0.57), PX: 114.87 (+3.05), CVX: 92.45 (+3.31), DOW: 46.70 (+1.07), REGN: 557.59 (+17.56)
Ventricular Fibrillation - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkvvmk/ventricular) has announced the addition of the "Ventricular Fibrillation Global Clinical Trials Review, H1, 2015" report to their offering. "Ventricular Fibrillation Global Clinical Trials Review, H1, 2015" provides data on the Ventricular Fibrillation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ventricular Fibrillation. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ventricular Fibrillation. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listing Top Companies/Institutions Participating in Ventricular Fibrillation Therapeutics Clinical Trials - Baxter International Inc. - Sanofi - Sandoz International GmbH - Ikaria Inc. - Gilead Sciences, Inc. - Gilead Sciences - National Heart, Lung, and Blood Institute - Assistance Publique - Hopitaux de Paris - Beaumont Health System - Department of Health, UK - Japan Heart Foundation - Japan Medical Association - Karolinska Institute - Klinikum der Ludwig-Maximilians-Universitat Munchen - Mayo Clinic - Rajaei Hospital For more information visit http://www.researchandmarkets.com/research/nk...entricular
GILD: 113.04 (+2.50), BAX: 38.08 (+0.38)
FCX, CLF, BIIB, COF: Jim Cramer's Views
at The Street - Mon Jul 27, 12:00AM CDT
Jim Cramer shares his views on a really bad day and when a leader stumbles. Freeport McMoRan, Google, Biogen and Capital One are among the many stocks discussed here.
BIIB: 317.50 (+8.07), COF: 78.35 (-0.26), GILD: 113.04 (+2.50), FCX: 12.49 (+1.12), RCPT: 227.76 (+0.67), CLF: 2.95 (+0.55), REGN: 557.59 (+17.56), CELG: 135.87 (+3.31)
